Illumina and the University Hospital of Tübingen Evaluate Potential of Whole Genome Sequencing to Improve Diagnosis of Full Range of Genetic Diseases
Go back to Illumina and the University Hospital of Tübingen Evaluate Potential of Whole Genome Sequencing to Improve Diagnosis of Full Range of Genetic Diseases| Illumina, Inc. (NASDAQ: ILMN) | Delayed: 117.54 +0.85 (0.73%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $116.69 | 52 Week High | $196.47 | |||
| Open | $117.69 | 52 Week Low | $127.10 | |||
| Day High | $119.22 | P/E | 130.60 | |||
| Day Low | $117.00 | EPS | $0.90 | |||
| Volume | 692,346 | |||||
